Documents

Fanapt and NEREUS drive growth as BYSANTI approval and pipeline advances set stage for expansion.

Directors elected, auditor ratified, and all proposals approved with no shareholder questions.

2026 revenue guidance raised on new launches, with BYSANTI and NEREUS set to drive future growth.

Strong product launches and pipeline progress position for substantial growth in 2026–2027.

Fanapt sales surged 26% year-over-year, NEREUS launched, and 2026 revenue guidance was raised.

BYSANTI and Nereus launches in 2026 drive growth amid expanding late-stage pipeline.

Poised for major 2026 growth with new approvals, strong pipeline, and rising prescription demand.

Imminent launches and label expansions position the portfolio for major near-term growth.

Strong pipeline and commercial growth expected, anchored by four FDA-approved therapies.

Fanapt's strong growth and Nereus approval drive 2025 results; 2026 revenue guidance up 13%.

Key regulatory milestones and strong financials support growth in psychiatry and neurology.

Robust late-stage pipeline and strong cash position drive growth across CNS and sleep therapies.

Q3 2025 revenue rose 18% year-over-year, driven by Fanapt's 31% sales growth and expanded launches.

Fanapt drives growth post-bipolar approval; three key regulatory milestones expected by 2026.

Advancing pipeline and commercial growth with key regulatory milestones and strong cash reserves.

Fanapt and milsaperidone drive growth, with up to six products targeted by 2026.

Fanapt drives Q2 growth with 27% sales increase; 2025 revenue guidance reaffirmed.

Q1 2025 revenue rose 5% to $50M, driven by Fanapt growth, with 2025 revenue guided up to $250M.